Compare ILAG & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILAG | SHPH |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 2.1M |
| IPO Year | 2020 | 2022 |
| Metric | ILAG | SHPH |
|---|---|---|
| Price | $3.10 | $3.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 694.0 | ★ 25.0K |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.38 |
| 52 Week High | $7.19 | $6.15 |
| Indicator | ILAG | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 54.79 |
| Support Level | $2.60 | $3.01 |
| Resistance Level | $3.38 | $4.64 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 47.24 | 64.10 |
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Taiwan.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.